Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5632043

CCC1CNCCN1c1ccc(F)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 9/20 0.44
SLC6A3 Q01959 9/20 0.44
SLC6A2 P23975 8/20 0.44
ADRB1 P08588 2/20 0.40
ALDH1A1 P00352 1/20 0.39
CYP2D6 P10635 3/20 0.38
KDM1A O60341 1/20 0.37
PIM1 P11309 1/20 0.37
TACR1 P25103 1/20 0.37
DPP4 P27487 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
FPR2 P25090 1/20 0.37
SCN9A Q15858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL5632440 1.00 SLC6A4 (0.44) SLC6A4SLC6A3SLC6A2ADRB1ALDH1A1
SCHEMBL5631142 0.88 SLC6A2 (0.50) SLC6A4SLC6A3SLC6A2ADRB1CYP2D6
SCHEMBL5632263 0.88 SLC6A2 (0.50) SLC6A4SLC6A3SLC6A2ADRB1CYP2D6
SCHEMBL5631151 0.88 SLC6A2 (0.50) SLC6A4SLC6A3SLC6A2ADRB1CYP2D6
Trifluoroacetic Acid SCHEMBL5630609 0.86 SLC6A4 (0.43) SLC6A4SLC6A3SLC6A2ADRB1CYP2D6
Trifluoroacetic Acid SCHEMBL5632735 0.86 SLC6A4 (0.43) SLC6A4SLC6A3SLC6A2ADRB1CYP2D6
Trifluoroacetic Acid SCHEMBL27649878 0.84 SLC6A4 (0.48) SLC6A4SLC6A3SLC6A2CYP2D6DPP4
Trifluoroacetic Acid SCHEMBL5633636 0.84 SLC6A4 (0.48) SLC6A4SLC6A3SLC6A2CYP2D6DPP4
Trifluoroacetic Acid SCHEMBL5633425 0.81 SLC6A4 (0.45) SLC6A4SLC6A3SLC6A2ADRB1CYP2D6
Trifluoroacetic Acid SCHEMBL27649808 0.81 SLC6A4 (0.45) SLC6A4SLC6A3SLC6A2ADRB1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070179155-A1 N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases ARENA PHARMACEUTICALS, INC. 2007-08-02 US disclosed
CN-1809545-A N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5HT2c ARENA PHARM INC (US) 2006-07-26 CN disclosed
EP-1644347-A1 N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT sb 2C /sb RECEPTOR ASSOCIATED DISEASES Arena Pharmaceuticals, Inc. (US) 2006-04-12 EP disclosed
WO-2005016902-A1 N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES ARENA PHARMACEUTICALS, INC. (US) 2005-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179155-A1 N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases HTR2C, HTR2A, HTR5A SLC6A4 56/4885SLC6A3 152/4885SLC6A2 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.